![]() |
市场调查报告书
商品编码
1792296
2025 年至 2033 年血管内动脉瘤修復市场报告(按适应症(腹主动脉瘤、胸主动脉瘤、胸腹主动脉瘤及其他)、产品、性别、年龄、最终用户和地区划分)Endovascular Aneurysm Repair Market Report by Indication (Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, and Others), Product, Gender, Age, End-User, and Region 2025-2033 |
2024 年全球血管内动脉瘤修復 (EVAR) 市场规模达 31 亿美元。展望未来, IMARC Group预计到 2033 年市场规模将达到 44 亿美元,2025-2033 年期间的成长率 (CAGR) 为 3.94%。
动脉瘤是指由于动脉壁薄弱或退化而扩大的动脉瘤。它通常与吸烟和吸烟有关。动脉瘤在患有动脉粥状硬化、高胆固醇和结缔组织疾病等疾病的人中也更容易发生。血管内动脉瘤修復术 (EVAR) 是一种微创手术,用于修復这些动脉瘤。 EVAR 手术是将覆膜支架(一种带有一层织物的金属网管)插入动脉的薄弱部位。这为血液提供了流动的通道,避免血液在凸起处积聚,并防止其破裂。如今,市面上有多种用于治疗动脉瘤的设备。
EVAR 治疗比传统手术更安全,因为无需手术。因此,该技术可缩短住院时间,并加快復原。由于动脉瘤的普遍存在以及老年人口的增长,血管内治疗正越来越多地被医疗保健提供者采用。人们越来越意识到该手术的潜在益处,这进一步推动了这一趋势。此外,世界各国政府正在实施多项计划,以改善成本结构,并向患者宣传 EVAR 设备和治疗方案的可用性。为此,医疗机构正在开发 EVAR 设备和技术,以加快康復速度并减少併发症。例如,增强型移植技术已经问世,该技术可以缩短治疗着陆区并提高对动脉曲率的适应性。这些技术进一步提高了 EVAR 手术的成功率。
The global endovascular aneurysm repair (EVAR) market size reached USD 3.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.4 Billion by 2033, exhibiting a growth rate (CAGR) of 3.94% during 2025-2033.
An aneurysm refers to the enlargement of the arterial wall due to weakness or degeneration. It is generally associated with tobacco consumption and smoking. The prevalence of aneurysms is also higher among people with medical conditions such as atherosclerosis, high cholesterol levels, and connective tissue disorder. Endovascular aneurysm repair (EVAR) refers to a minimally invasive procedure or surgery that is performed to repair these aneurysms. EVAR procedure is performed by inserting a covered stent, a metal mesh tube with a layer of fabric, into the weak area of the artery. This provides a route for the blood to flow without accumulating in the bulge and prevents it from bursting. Nowadays, multiple devices are available in the market that are used to treat aneurysms.
The EVAR treatment is comparatively safer than traditional procedures, as there is no need for performing surgery. As a result, this technique results in short hospital stays and quicker recovery. Due to the prevalence of aneurysms, along with the growing geriatric population, endovascular treatment is increasingly being adopted by healthcare providers. This has further been supported by the rising awareness of the potential benefits of the procedure. Also, governments across the globe are undertaking several programs to improve the cost structure and spread awareness about the availability of EVAR devices and treatment procedures among patients. In line with this, healthcare institutions are developing EVAR devices and technologies that offer faster recovery and fewer complications. For instance, enhanced graft technologies have been created, which allow treatments with short landing zones and improve conformability to the artery curvature. These technologies have further helped in increasing the success rate of EVAR procedures.
The report has also analyzed the competitive landscape of the market with some of the key players being Medtronic plc, Cook Group Incorporated, W. L. Gore & Associates, Inc., Bolton Medical, Inc., Gamida Cell Ltd., JOTEC GmbH, Getinge AB (Maquet), Shanghai MicroPort Medical (Group) Co., Ltd., Terumo Corporation, Endologix, Inc., Lombard Medical Limited, and Cardinal Health, Inc.